GALANTAMINE tablet, film coated

Nchi: Marekani

Lugha: Kiingereza

Chanzo: NLM (National Library of Medicine)

Viambatanisho vya kazi:

GALANTAMINE HYDROBROMIDE (UNII: MJ4PTD2VVW) (GALANTAMINE - UNII:0D3Q044KCA)

Inapatikana kutoka:

American Health Packaging

INN (Jina la Kimataifa):

GALANTAMINE HYDROBROMIDE

Tungo:

GALANTAMINE 4 mg

Njia ya uendeshaji:

ORAL

Dawa ya aina:

PRESCRIPTION DRUG

Matibabu dalili:

Galantamine tablets are indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. Galantamine tablets are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. Risk Summary There are no adequate data on the developmental risk associated with the use of galantamine hydrobromide in pregnant women. In studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically (see Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Animal Data In rats, administration of galantamine (

Bidhaa muhtasari:

How Supplied Galantamine tablets USP are supplied as follows: Galantamine Tablets USP, 4 mg are off-white, circular, biconvex, film-coated tablets debossed with ‘F’ on one side and ‘49’ on the other side. Unit dose packages of 30 (3 x 10) NDC 68084-729-21 Storage and Handling Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep out of reach of children. FOR YOUR PROTECTION: Do not use if blister is torn or broken.

Idhini hali ya:

Abbreviated New Drug Application

Tabia za bidhaa

GALANTAMINE- GALANTAMINE TABLET, FILM COATED
AMERICAN HEALTH PACKAGING
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
GALANTAMINE TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
GALANTAMINE TABLETS.
GALANTAMINE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 2001
INDICATIONS AND USAGE
Galantamine tablets are a cholinesterase inhibitor indicated for the
treatment of mild to moderate
dementia of the Alzheimer’s type ( 1)
DOSAGE AND ADMINISTRATION
Galantamine tablets: recommended starting dosage is 4 mg twice daily;
increase to initial maintenance
dosage of 8 mg twice daily after a minimum of 4 weeks. Based on
clinical benefit and tolerability,
dosage may be increased to 12 mg twice daily after a minimum of 4
weeks at 8 mg twice daily. ( 2.2)
Take with food; ensure adequate fluid intake during treatment ( 2.2)
Hepatic impairment: should not exceed 16 mg/day for moderate hepatic
impairment; do not use in
patients with severe hepatic impairment ( 2.3)
Renal impairment: should not exceed 16 mg/day for creatinine clearance
9 to 59 mL/min; do not use in
patients with creatinine clearance less than 9 mL/min ( 2.4)
DOSAGE FORMS AND STRENGTHS
Tablets – 4 mg, 8 mg, 12 mg (3)
CONTRAINDICATIONS
Known hypersensitivity to galantamine hydrobromide or any excipients (
4)
WARNINGS AND PRECAUTIONS
Serious skin reactions: discontinue at first appearance of skin rash (
5.1)
All patients should be considered at risk for adverse effects on
cardiac conduction, including
bradycardia and AV block, due to vagotonic effects on sinoatrial and
atrioventricular nodes ( 5.3)
Active or occult gastrointestinal bleeding: monitor, especially those
with an increased risk for developing
ulcers ( 5.4)
Cholinomimetics may cause bladder outflow obstruction ( 5.5)
Monitor for respiratory adverse events in patients with a history of
severe asthma or obstructive
pulmonary disease ( 5.7)
ADVERSE REACTIONS
The most common adverse reactions (≥5%) were nausea, vomiting,